Erişkinlerde Aşılama
Aşılama çocuklar için oldıuğu kadar erişkinler için de önemlidir. Ancak çoğu erişkin yetersizaşılanmaktadır. Yeni çalışmalar ortalama yılda 30 bin erişkinin aşı ile önlenebilir hastalıklardanöldüğünü göstermektedir. Erişkin aşılama oranları artmakla birlikte hala DünyaSağlık Örgütü (DSO) “Sağlıklı Kişiler 2020” hedeflerinden uzaktır. Erişkin aşılaması morbiditeve mortaliteyi önemli oranda azaltmasına rağmen, pek çok erişkin kendileri için gerekliolan aşıların farkında değildir. Özellikle infeksiyon hastalıkları için risk grubunda olankronik hastalıkları olan bireyler, yaşlılar, sağlık çalışanlarının aşılanmaları pek çok yaşamı korumapotansiyeline sahiptir. ACİP erişkinler için 12 aşı önermektedir. Erişkin aşılaması birincibasamakta rutin hasta bakımının temel elementi olmalıdır.
___
- 1. National Foundation for İnfectious Diseases. Adult Vaccination Saves
Lives. 2012. Erişim: www.adultvaccination.org/resources/ctaadult.
pdf. Erişim tarihi 15.04.2015.
2. Healthy People 2020. Erişim. http://www.healthypeople.gov/2020/topics-
objectives/topic/immunization-and-infectious-diseases Erişim tarihi:
09.04. 2015.
3. Global Vaccine Action Plan, World Health Organization 2013, The Sixtyfifth
World Health Assembly
4. Orenstein WA, Atkinson WL. Immunisation in Goldman L, Schafer AI
et al (ed) Goldman's Cecil Medicine 24.th ed. Elservier Saunders Philadelphia
2012 pp. 63-75:16
5. Parkins MD, McNeil SA, Laupland KB. Routine immunization of adults
in Canada: Review of the epidemiology of vaccine-preventable diseases
and current recommendations for primary prevention. Can J Infect
Dis Med Microbiol. 2009;20(3):e81-e91
6. Sinclair D, Walker T. International Longevity Center. Adult Vaccination:
A Key Component Of Healthy Ageing. The Benefits Of Life-Course
immunisation İn Europe, 2013. Erişim: http://www.ilcuk.org.uk/
images/uploads/publication-pdfs/Adult_vaccination_-_a_key_component_
of_health_ageing.pdf. Erişim tarihi: 09.04. 2015.
7. Ward JI, Cherry JD, Chang S-J, Partridge S. Efficacy of an Acellular
Pertussis Vaccine among Adolescents and Adults. N Engl J Med,
353;15:1555-64
8. Measles Outbreaks Include Unvaccinated Healthcare Workers. Medscape.
May 29, 2015.
9. WHO recommendations for routine immunization - summary tables.
http://www.who.int/immunization/policy/immunization_tables/en/
10. CDC. Recommended Adult Immunization Schedule, United States –
2016 erişim: http://www.cdc.gov/vaccines/schedules/downloads/
adult/adult-combined-schedule.pdf. Erişim tarihi: 09.04. 2015.
11. Kim DK, Bridges CB, Harriman KH, Advisory Committee on Immunization
Practices. Advisory committee on immunization practices recommended
immunization schedule for adults aged 19 years or older:
United States, 2015. Ann Intern Med 2015; 162:214.
12. Public Health Agency of Canada. Canadıan Immunization Guide 2014
erişim.
13. Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid
fat pad thickness. Implications for needle length in adult immunization.
JAMA 1997; 277:1709
14. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy
for global use: Report of theNomenclature Review Committee
of the World Allergy Organization, October 2003. J Allergy ClinImmunol
2004; 113:832.
15. Centers for Disease Control and Prevention (CDC). Tetanus surveillance
United States, 2001-2008.MMWR Morb Mortal Wkly Rep 2011;
60:365.
16. Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration
of a reduced antigen content diphtheria and tetanus toxoids and acellular
pertussis vaccine in young adults. Clin Infect Dis 2010;51:656.
17. Centers for Disease Control and Prevention. Vaccines and Immunizations.
Pertussis. Epidemiology and
18. Centers for Disease Control and Prevention (CDC). Updated Recommendations
for Use of TetanusToxoid, Reduced Diphtheria Toxoid, and
Acellular Pertussis (Tdap) Vaccine in Adults Aged 65 Years and Older
Advisory Committee on Immunization Practices (ACIP), 2012.
MMWR Morb Morta Wkly Rep 2012; 61:468.
19. Liu BC, McIntyre P, Kaldor JM, et al. Pertussis in older adults: prospective
study of risk factors and morbidity. Clin Infect Dis 2012; 55:1450
20. Maple PA, Efstratiou A, George RC, et al. Diphtheria immunity in
UK blood donors. Lancet 1995;345:963.
21. CDC Vaccination Coverage in the U.S. Erişim : http://www.cdc.gov/
vaccines/imzmanagers/ coverage/imzcoverage.html Erişim tarihi:
27.04.2015
22. Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus.
Lancet 2015; 385:362.
23. National Center for Immunization and Respiratory Diseases, Division
of Viral Diseases. Documentationand Verification of Measles,
Rubella and Congenital Rubella Syndrome Elimination in the Region
of theAmericas: United States National Report, March 28,
2012. Erişim: http://www.cdc.gov/measles/downloads/Reporteliminationmeaslesrubellacrs.
pdf Erişim tarihi 27.4.2015
24. Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB, Wallace
GS. Measles — United States, January 4–April 2, 2015. Morbidity
and Mortality Weekly Report. 2015;64(14):373-376.
25. Advisory Committee on Immunization Practices (ACIP), Fiore AE,
Wasley A, Bell BP. Prevention of hepatitis A through active or passive
immunization: recommendations of the Advisory Committee on
Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1
46 www.kliniktipdergisi.com
26. Prevention of hepatitis A through active or passive immunization: recommendations
of the AdvisoryCommittee on Immunization practices
(ACIP). MMWR Recomm Rep 2007; 56.
27. Xu Z-Y, Wang X-Y. Live attenuated hepatitis A vaccines developed
in China. Human Vaccines & Immunotherapeutics 2014;10(3):
659–666
28. WHO. Weekly epidemiological record. Live attenuated hepatitis A vaccine
Releve Epidemiologique Hebdomadaire, No 30, 2010 pp:289-90
29. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment,
and current and emerging prevention and control measures.
J Viral Hepat 2004; 11:97.
30. Akdeniz M, Mevsim G. Gripte Güncel Gelişmeler. Klinik Tıp Aile Hekimliği
2015: 2015;7(2): 7-15
31. WHO, Candidate vaccine viruses and potency testing reagents for
development and production of vaccines for use in the northern hemisphere
2015-2016 influenza season. Erişim: http://www.who.int/influenza/
vaccines/virus/candidates_reagents/2015_16_north/eInfluenza.
Erişim tarihi: 27.4.2015
32. Glezen WP. Clinical practice. Prevention and treatment of seasonal
influenza. N Engl J Med 2008;359:2579.
33. ACIP Releases Updated Recommendations on Influenza Vaccination
to Include the 2014–2015 Season. Am Fam Physician.
2014;90(8):584-587.
34. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Va´zquez M. Influenza
Vaccine Given to Pregnant Women Reduces Hospitalization
Due to Influenza in Their Infants. Clinical Infectious Diseases 2010;
51(12):1355–1361
35. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D at al. Efficacy
of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults.
N Engl J Med 2014; 371:635-645
36. Centers for Disease Control and Prevention. Epidemiology and Prevention
of Vaccine-Preventable Diseases, 13th Edition, 2015. Pneumococcal
disease http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/
pneumo.pdf
37. Centers for Disease Control and Prevention (CDC). Licensure of 13valent
pneumococcal conjugate vaccine for adults aged 50 years and
older. MMWR Morb Mortal Wkly Rep 2012; 61:394.
38. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13valent pneumococcal
conjugate vaccine and 23valent pneumococcal polysaccharide
vaccine among adults aged ≥65 years: recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR Morb
Mortal Wkly Rep 2014; 63:822.
39. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes
zoster and postherpetic neuralgia in older adults. N Engl J Med
2005; 352:2271.
40. Morrison VA, Johnson GR, Schmader KE, et al. Longterm Persistence
of Zoster Vaccine Efficacy. Clin Infect Dis 2015; 60:900.
41. Centers for Disease Control and Prevention. Herpes Zoster Vaccination.
Erişim. http://www.cdc.gov/vaccines/vpd-vac/shingles/hcpvaccination.
htm. Erişim tarihi: 27.4.2015
42. Lal H, Cunningham AL, Godeaux O, Chlibek R et al. Efficiacy of an
adjuvanted Herpes Zoster Subunit vaccşne in older adults. N Engl
J Med. 2015;372(22):2087-2096
43. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus
vaccination: recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep 2014; 63(No.RR-
05):1-30.
44. de Sanjosé S, Alemany L, Ordi J, et al. Worldwide human papillomavirus
genotype attribution in over 2000 cases of intraepithelial and
invasive lesions of the vulva. Eur J Cancer 2013; 49:3450.
45. American College of Obstetricians and Gynecologists. ACOG committee
opinion no. 588: Human Papillomavirus vaccination. Erişim.
http://www.acog.org/-/media/Committee-Opinions/Committee-on-
Adolescent-Health Care/co588.pdf. Erişim tarihi: 29.4.2015
46. U.S. Food and Drug Administration. FDA approves Gardasil 9 for
prevention of certain cancers caused by five additional types of HPV.
Erişim. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm426485.htm. Erişim tarihi: 29.4.2015.
47. Petrovsky E, Bocchini JA, Hariri S, Chesson H et al. Use of 9-Valent
Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination
Recommendations of the Advisory Committee on Immunization
Practices. MMWR ,2015;64(11): 300-304
48. Leah M. Smith LM, Strumpf EC, Kaufman JS, Lofters A et al. The
Early Benefits of Human Papillomavirus Vaccination on Cervical
Dysplasia and Anogenital Warts. Pediatrics 2015;135(5):e1132- e1144
49. CDC. Guidelines for Vaccinating Pregnant Women. Erişim.
http://www.cdc.gov/vaccines/pubs/preg-guide.htm. Erişim tarihi:
29.4.2015
50. Chu HY, Englund JA. Maternal immunization. Clin Infect Dis
2014; 59:560.
51. Keller-Stanislawski B, Englund JA, Kang G, et al. Safety of immunization
during pregnancy: a review of the evidence of selected inactivated
and live attenuated vaccines. Vaccine 2014; 32:7057.
52. Forsyth K, Plotkin S, Tan T, Von Konig CHW, Strategies to decrease
Pertussis Transmission to infants. Pediatrics 2015;135(6);e1475-e1482.
53. MacDonald NE, McDonald JC. Canadian Paediatric Society Infectious
Diseases and Immunization Committee, The benefits of influenza
vaccine in pregnancy for the fetus and the infant younger than
six months of age. Paediatr Child Health 2014;19(9):e121-22
54. Brydak LB, Nitsch-Osuch A. Vaccination against influenza in pregnant
women. Acta Biochimica Polonica 2014;61(3):589-91.
55. Steinhoff MC, Omer SB. A review of fetal and infant protection associated
with antenatal influenza immunization. American Journal
of Obstetrics & Gynecology. 2012, suplement
56. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice
guideline for vaccination of the immunocompromised host. Clin
Infect Dis 2014; 58:e44.
57. Hibberd PA, Boeck M, Poplack DG, Thorner AR. Immunizations in
patients with cancer. http://www.uptodate.com/contents/immunizations-
in-patients-with-cancer.
58. DanzigerIsakov L, Kumar D, AST Infectious Diseases Community
of Practice. Vaccination in solid organ transplantation. Am J
Transplant 2013; 13 Suppl 4:311.
59. Centers for Disease Control (U.S). Advice for travelers. Treat Guidel
Med Lett 2009; 7:83.
60. World Health organizatıon. International travel and health erişim.
http://www.who.int/ith/links/national_links/en/ Erişim tarihi: 29.4.2015
61. 104. CDC. Yellow Book Erişim: Homepage.http://wwwnc.cdc.gov/travel/
page/yellowbookhome2014. Erişim tarihi 27.04.2015
62. Turhan Ö, Polat HH, Öncel S, Akcan Aet al. Pneumococcal Vaccination
Status in Adults Sixty-Five Years and Older, Kuwait Medical
Journal 2010; 42 (2): 135-138
63. Zeybek Y, Tokalak İ, Boyacıoğlu S. Altmış beş yaş ve üzeri erişkinlerde
aşılanma Durumu. Türk Geriatri Dergisi 2004; 7 (3): 152-154.
64. Aşık Z, Çakmak T, Bilgili P. Erişkinlerin erişkinlik dönemi aşıları hakkındaki
bilgi, tutum ve davranışları, Türk Aile Hek Derg
2013;17(3):113-118